Company news

Nxera Pharma Co., Ltd. news in 2025

Nxera Pharma Co., Ltd.'s news releases, calls and decks from 2025, newest first.

View company

Nxera Pharma to Regain Full Rights to GPR52 Agonist Program for Schizophrenia

December 18, 2025

Nxera Introduces Employee Stock Ownership Plan (J-ESOP) for Employees Residing in Japan

November 19, 2025

Nxera Pharma Shares Video Interviews with Major Shareholders on Its Official YouTube Channel

November 17, 2025

Nxera Announces Focused Restructuring to Enhance Path to Profitability

November 17, 2025

Nxera Pharma to Host R&D Day 2025

November 4, 2025

Nxera’s President & CEO to Participate in a ‘Fireside Chat’ at the Jefferies London Healthcare Conference 2025

October 31, 2025

Nxera Pharma Receives a Manufacturing Approval Partial Amendment Regarding the Addition of a Manufacturing Site in Asia for QUVIVIQ® 25 and 50 mg

October 31, 2025

Nxera Pharma Operational Highlights and Consolidated Results for the Third Quarter and First Nine Months of 2025

October 31, 2025

Nxera’s Partner Cancer Research UK Presents Data from Successfully Completed Phase 1 Clinical Trial of Cancer Immunotherapy Drug HTL0039732 at ESMO

October 21, 2025

Nxera Pharma and Cancer Research UK Announce First Patient Dosed in Phase 2a Trial of Investigational Cancer Immunotherapy HTL0039732

September 16, 2025

Nxera Pharma Operational Highlights and Consolidated Results for the Second Quarter and First Half 2025

August 8, 2025

Nxera Launches Broad Proprietary Pipeline Targeting Obesity and Chronic Weight Management

August 5, 2025

Nxera Pharma to Receive US$4.8 Million in Milestone Payments Following Centessa’s Initiation of Clinical Development of ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist

July 4, 2025

Nxera Pharma to Receive US$15 Million from Neurocrine Biosciences Following Dosing of First Patient in Phase 3 Trial of NBI-1117568

June 2, 2025

Nxera Pharma Achieves Development Milestone in Collaboration with Eli Lilly Targeting Metabolic Diseases

June 1, 2025

Nxera Pharma Operational Highlights and Consolidated Results for the First Quarter 2025

May 2, 2025

Nxera Pharma’s Partner Neurocrine Biosciences Initiates Phase 3 Registrational Program of NBI-1117568 as a Potential Treatment for Adults with Schizophrenia

April 30, 2025

Nxera Pharma Appoints Top-Ranked Biopharma Investment Analyst Shinya Tsuzuki as Head of Investor Relations

April 30, 2025

Calls in 2025

Decks in 2025